Company intelligence / Profile preview

ProCore

Ness Ziona, Central, Israelprocore.com ↗

Ownership: Private
Development stage: Commercial

Overview

RegenoGel products are commercially available in Israel for joint and bone disease treatment. The company participates in EU-funded research consortia focused on cartilage repair/regeneration. Clinical results have enabled regulatory approval locally; further data may be available through academic collaborations but is not detailed publicly.

Therapeutic areas: Rheumatology
Modalities: BiologicBiomaterial-based therapy
Industry: Implantable Medical Devices

Partnerships

EU-funded research consortia under FP7 and Horizon2020 MSCA programs for cartilage repair/regeneration

Beyond the preview

Go deeper on ProCore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProCore.

Explore the full profile